Effect of Botulinum Neurotoxin A Injection into the Submucoperichondrium of the Nasal Septum in Reducing Idiopathic Non-Allergic Rhinitis and Persistent Allergic Rhinitis | ||
| Iranian Journal of Otorhinolaryngology | ||
| مقاله 1، دوره 27، شماره 4، مهر 2015، صفحه 253-259 اصل مقاله (304.35 K) | ||
| نوع مقاله: Original | ||
| شناسه دیجیتال (DOI): 10.22038/ijorl.2015.4514 | ||
| نویسندگان | ||
| Keramat Mozafarinia1؛ Mehdi Abna* 1؛ Narges khanjani2 | ||
| 1Department of Otorhinolaryngology, Medical School, Kerman University of Medical Sciences and Health Services, Kerman, Iran. | ||
| 2Neurology Research Center, Shafa Hospital, Kerman University of Medical Sciences and Health Services, Kerman, Iran. | ||
| چکیده | ||
| Introduction: Submucoperichondrial injection of botulinum neurotoxin A (BTA) in the nasal septum is a promising therapeutic option in the treatment of persistent allergic rhinitis (AR) and non-allergic rhinitis, and is safer and more effective than intraturbinate injection in reducing clinical symptoms. Materials and Methods: Forty patients diagnosed with persistent AR or non-allergic rhinitis referred to Shafa Medical Center affiliated to Kerman University of Medical Sciences were included in this study and were randomly allocated to the intervention or control groups. Patients received an injection of 80 units BTA (Dysport, Ipsen Ltd Company, UK) at a concentration of 200 mU/ml in normal saline on four spots in each side of the nose and were followed for 12 weeks. Data were analyzed using a chi-square or Fisher’s test, and Mann Whitney U test. Results: The mean age of patients was 46.1±15.3 years, and the two groups did not differ significantly in demographic variables. The severity of rhinitis symptoms was reduced after 4 weeks of injections in the intervention group and then gradually decreased further until the 12th week. There was a statistically significant difference between the groups (P<0.05). No adverse effects were reported. Conclusion: Submucoperichondrial BTA injection can be considered an effective therapeutic option in patients with persistent AR and idiopathic rhinitis. In comparison with other injection techniques, submucoperichondrial BTA injection has fewer side effects with a longer period of effectiveness, and is easy to perform and is more tolerable for the patient. | ||
| کلیدواژهها | ||
| Botulinum neurotoxin A؛ Persistent allergic rhinitis؛ Idiopathic rhinitis؛ Submucoperichondrial injection | ||
| مراجع | ||
|
1. Flint PW, Haughey BH, Lund VJ, Niparko JK, Richardson MA, Robbins KT, et al. Nonallergic Rhinitis. In: Cummings CW, Flint PW, Harker LA, Haughey BH, Richardson MA, Robbins KT, et al. (editors). Cummings Otolaryngology Head & Neck Surgery. 5th ed. Philadelphia: Mosby; 2010: 694–701.
2. Tran NP, Vickery J, Blaiss MS. Management of rhinitis: allergic and non-allergic. Allergy asthma Immunol Res 2011;3(3):148–56.
3. Greiner AN, Hellings PW, Rotiroti G, Scadding GK. Allergic rhinitis. Lancet 2012; 378 (9809): 2112–22.
4. Rohrbach S, Junghans K, Köhler S, Laskawi R. Minimally invasive application of botulinum toxin A in patients with idiopathic rhinitis. Head Face Med 2009; 5:18.
5. Braun T, Gürkov R, Kramer MF, Krause E. Septal injection of botulinum neurotoxin A for idiopathic rhinitis: a pilot study. Am J Otolaryngology. 2012; 33(1): 64–7.
6. Yang TY, Jung YG, Kim YH, Jang TY. A comparison of the effects of botulinum toxin A and steroid injection on nasal allergy. Otolaryngol Head Neck Surg 2008; 139(3):367–71.
7. Ozcan C, Vayisoglu Y, Dogu O, Görür K. The effect of intranasal injection of botulinum toxin A on the symptoms of vasomotor rhinitis. Am J Otolaryng 2006; 27(5):314–8.
8. Spaci T, Yazici S, Fatih Evcmike M, Bozkurt Z, Karavus A, Ugurlu B, et al. Investigation of the effects of intranasal botulinum toxin type a and ipratropium bromide nasal spray on nasal hypersecretion in idiopathic rhinitis without eosinophilia. Rhinology 2008; 46(1):45–51.
9. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA (2) LEN and AllerGen). Allergy 2008; 63:8–160.
10. Razi, MZ. Al-havi. Mashhad: Mashhad University of Medical Sciences; 2009. (Persian)
11. Waite KJ. Blackley and the development of hay fever as a disease of civilization in the nineteenth century. Med Hist 1995; 39(2):186–96.
12. Bernstein JA, Davis BP, Picard JK, Cooper JP, Zheng S, Levin LS. A randomized, double-blind, parallel trial comparing capsaicin nasal spray with placebo in subjects with a significant component of nonallergic rhinitis. Ann Allergy Asthma Immunol 2011; 107(2): 171–8.
13. Abtahi SM, Hashemi SM, Abtahi SH, Bastani B. Septal injection in comparison with inferior turbinates injection of botulinum toxin A in patients with allergic rhinitis. J Res Med Sci 2013; 18(5):400–4) Persian).
14. Wen WD, Yuan F, Hou YP, Song YF. Experimental studies for botulinum toxin type A on allergic rhinitis in the rat. Zhonghua Er Bi Yan Hou Ke Za Zhi 2004; 39(2):97–101.
15. Unal M, Sevim S, Dogu O, Vayisoğlu Y, Kanik A. Effect of botulinum toxin type A on nasal symptoms in patients with allergic rhinitis: A double-blind, placebo-controlled clinical trial. Acta Otolaryngol 2003;123(9):1060–3. | ||
|
آمار تعداد مشاهده مقاله: 2,424 تعداد دریافت فایل اصل مقاله: 1,745 |
||